Effectiveness of cinacalcet in patients with chronic kidney disease and secondary hyperparathyroidism not receiving dialysis

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Pérez Ricart, Ariadna ^a,c   Galicia Basart, Maria ^a   Alcalde Rodrigo, Maria ^a   Segarra Medrano, Alfons ^a   Suñé Negre, Josep Maria ^b   Montoro Ronsano, José Bruno ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D; VITAMIN D DERIVATIVE; CALCIMIMETIC AGENT; PARATHYROID HORMONE;

AGED; ALOPECIA; ARTICLE; CALCIUM BLOOD LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MALE; MUSCLE SPASM; OBSERVATIONAL STUDY; PARESTHESIA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; BLOOD; COMPLICATION; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; OFF LABEL DRUG USE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CALCIMIMETIC AGENTS; CALCIUM; CINACALCET HYDROCHLORIDE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; OFF-LABEL USE; PARATHYROID HORMONE; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84990855291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161527     Document Type: Article

References (32)

1. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921. doi: 10.2215/CJN.06040710 PMID: 21454719
2. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism in chronich kidney disease. Am J Kidney Dis. 2003; 42 (Suppl. 3):S1-S202
3. Kidney Disease Improving Global Outcomes Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009: 76 Suppl 113:S1-S130
4. Verheyen N, Pilz S, Eller K, Kienreich K, Fahrleitner-Pammer A, Pieske B et al. Cinacalcet hydrochloride for the treatment of hyperparathyroidism Expert Opin. Pharmacother 2013; 14(6):793-806
5. Food and Drug Administration. Sensipar®, 2004; revised November 2014. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021688s20-21-22lbl.pdf Accessed January 29, 2016
6. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco A LM, Shivinder J et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2009; 53:197-207 doi: 10.1053/j.ajkd.2008.09.021 PMID: 19110359
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. PMID: 1244564
8. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW et al. Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clin Chem 2007; 53(4):766-72 PMID: 17332152
9. Charytan C, Cobrun JW, Chonchol M, Herman J, Kien YH, Liu W et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46(1):56-58
10. Montenegro J, Cornago I, Gallardo I, García-Ledesma P, Hernando A, Martinez I et al. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis. Nephrology 2012; 17:26-31 doi: 10.1111/j.1440-1797.2011.01530.x PMID: 22022934
11. Miguel JL, Romero S, Madero R, Martinez J, Azorin S, Selgas R. ¿Controla el cinacalcet el hiperparatiroidismo secundario en pacientes con insuficiencia renal crónica estadio V no dializados? V Interantional Symposium Advances in Bone and Mineral Disorders in CKD, Oviedo, 2009.
12. Ramos A, Albalate M, Martin C, Manrique MP, Fernandez B, Riani G et al. Induccion a la remision clinica de hiperparatiroidismo secundario (HPTH 2°) con cinacalcet en enfermedad renal cronica (ERC) estadios 4 y 5 sin hemodialisis. 39 Congreso Sociedad Española de Nefrología, Pamplona, 2009.
13. Forslund T, Loistinen A, Miettinen M. Experience with cinacalcet for secondary hyperparathyroidism in patients with chronic kidney disease stage III and IV. Clinical Medicine: Therapeutics 2009; 1 801-808
14. Segura P, Borrego FJ, Sánchez MC, García MJ, Biechy MM, Pérez V. Analysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in haemodialysis patients. Nefrologia 2010; 30(4):443-51 doi: 10.3265/Nefrologia.pre2010.May.10451 PMID: 20651886
15. National Institute for Health and Clinical Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy NICE technology appraisal guidance 117, January 2007. Available from https://www.nice.org.uk/guidance/ta117/resources/guidance-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-endstage-renal-disease-on-maintenance-dialysis-therapy-pdf. Accessed July 29, 2015
16. Mercadal G, Blasco I. Evaluación retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta. Farm Hosp 2012; 36(1):11-15 doi: 10.1016/j.farma.2010.10.008 PMID: 21514862
17. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516-25. PMID: 15071126
18. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3:1718-1725. doi: 10.2215/CJN.01040308 PMID: 18945995
19. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23: 2311-2318 doi: 10.1093/ndt/gfn026 PMID: 18310602
20. Ureña-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 2013; 28:1241-1254 doi: 10.1093/ndt/gfs568 PMID: 23328710
21. Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B et al. The OPTIMA Study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3:36-45 doi: 10.2215/CJN.03591006 PMID: 18178780
22. Moe SM, Chertow GM, Coburn JW, Quarles D, Goodman WG, Block GA. Achieving NKF-K/DOQITM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International 2005; 67: 760-771 PMID: 15673327
23. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB et al. Cinacalcet HCl, an oral calci-mimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807 PMID: 15689407
24. Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N et al. Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant 2009; 24:2852-2859 doi: 10.1093/ndt/gfp144 PMID: 19369690
25. Bover J, Pérez R, Molina M, Benavides B, Ariza F, Miguel JL et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. Nephron Clin Pract 2011; 118:c109-c121 doi: 10.1159/000319882 PMID: 21150219
26. Górriz JL, Molina P, Bover, Barril G, Martín-de Francisco AL, Caravaca F J et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrologia 2013; 33(1):46-60 doi: 10.3265/Nefrologia.pre2012.Nov.11703 PMID: 23364626
27. Chonchol M, Wuthrich RP. Potential future uses of calcimimetics in patients with chronic kidney disease. NDT Plus 1 2008;[Suppl 1:]: i36-i41 doi: 10.1093/ndtplus/sfm043 PMID: 25983955
28. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J et al. Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020 PMID: 18514987
29. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ et al. Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease. JAMA 2011; 305(11):1119-1127 doi: 10.1001/jama.2011.308 PMID: 21406649
30. Stompór T. Coronary artery calcification in chronic kidney disease. An Update World J Cardiol 2014; 6(4):115-129 doi: 10.4330/wjc.v6.i4.115 PMID: 24772252
31. Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract Neph 2008; 4(7):364-365
32. Hervás JG, Prados MD, Polo A, Cerezo S. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. Nefrologia 2011; 31(6):697-706 doi: 10.3265/Nefrologia.pre2011.Aug.11030 PMID: 22130286